DKSH has partnered with Accord Healthcare to expand and solidify its generic drugs business in the Philippines.
Media release
Manila, March 10, 2021 – DKSH Business Unit Healthcare, Asia's leading partner for healthcare companies seeking to grow their business in Asia and beyond, and Accord Healthcare, one of the largest suppliers of generic medicines, have announced their exclusive partnership in the Philippines. DKSH will offer full-agency services to Accord Healthcare by growing their existing portfolio and launching new products into the market. The agreement complies with DKSH's strategic direction of strengthening its regional footprint in the Philippines as well as expanding into the generics market.
Accord Healthcare is an award-winning pharmaceutical company headquartered in the UK and driven to think outside the box to provide more patients around the world with access to essential and affordable medicines. With operations in over 80 countries worldwide and a pan-European footprint of more than 45 countries. Accord Healthcare develops, manufactures, and distributes affordable medicines. The company has one of the most active launch programs in the European pharmaceutical sector.
As a strategic partner, DKSH will help Accord Healthcare with commercial outsourcing and growth prospects to solidify their brand presence and gain market share. DKSH's experienced teams and broad distribution network will ensure Accord Healthcare's products reach hospitals, clinics, chain pharmacies and eventually patients in need across the country.
Bonnibelle Santiago, Business Manager, Accord Healthcare, said: “This partnership will enable us to foster our reputation for quality and integrity by addressing the growing patient needs for affordable access to high-quality generic drugs, while expanding our portfolio in the country.”
Carlo Dominique, Assistant General Manager, Business Unit Healthcare, DKSH, commented: “This agreement demonstrates our commitment to enrich people's lives. We provide the best possible commercial outsourcing services to our clients, so that they, in turn, can focus on their core competencies of developing excellent products to improve the lives of patients. Through working with Accord Healthcare, we are proud to improve access to high-quality generic drugs for a lot of Filipino patients, while being committed to driving growth and strengthening the commercial footprint in the Philippines for our partner.”
For further information, please contact:
DKSH Business Unit Healthcare
Sheena Flannery
Director, Group Communications
+66 2 220 9739
sheena.flannery@dksh.com
About Accord Healthcare
Headquartered in the United Kingdom (UK), Accord Healthcare Europe is one of the fastest growing pharmaceutical companies in Europe. Accord has one of the largest market footprints of any European generic and biosimilars companies selling generic medicines in over 80 countries around the world. This global footprint enables us to deliver vital, affordable medicines to national health systems supporting healthcare professionals to transform patient lives worldwide. Our approach is agile and inventive, always seeking to improve our products and patients’ access to them. We’re driven to think differently and deliver more for the benefit of patients worldwide.
www.accord-healthcare.com
About DKSH
At DKSH, our purpose is to enrich people’s lives. For more than 150 years, we have been delivering growth for companies in Asia and beyond across our Business Units Healthcare, Consumer Goods, Performance Materials and Technology. As a leading Market Expansion Services provider, we offer sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 32,450 specialists, generating net sales of CHF 10.7 billion in 2020. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and over-the-counter (OTC) products as well as medical devices. With around 7,970 specialists, the Business Unit generated net sales of CHF 5.4 billion in 2020. www.dksh.com/hec